Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance

Xingxiang Pu 1,2, Lin Wu 2, Dan Su 3, Weimin Mao 4 and Bingliang Fang 1*

Abstract
Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the United States and worldwide. Here we provide an overview of recent progress in immune checkpoint blockade therapy for treatment of non-small cell lung cancer (NSCLC), and discuss biomarkers associated with the treatment responses, mechanisms underlying resistance and strategies to overcome resistance. The success of immune checkpoint blockade therapies is driven by immunogenicity of tumor cells, which is associated with mutation burden and neoantigen burden in cancers. Lymphocyte infiltration in cancer tissues and interferon-γ-induced PD-L1 expression in tumor microenvironments may serve as surrogate biomarkers for adaptive immune resistance and likelihood of responses to immune checkpoint blockade therapy. In contrast, weak immunogenicity of, and/or impaired antigen presentation in, tumor cells are primary causes of resistance to these therapies. Thus, approaches that increase immunogenicity of cancer cells and/or enhance immune cell recruitment to cancer sites will likely overcome resistance to immunotherapy.

Keywords: Immune checkpoint inhibitors, PD-1, PD-L1, Predictive biomarkers, Resistance

Introduction
Recent breakthroughs in immunotherapy for cancer have changed clinical practice in the treatment of lung cancer, a deadly disease that each year causes about 155,000 deaths in the United States and approximately 1.6 million deaths worldwide [1, 2]. Since 2015, four immune checkpoint inhibitors (ICIs), anti–PD-1 antibodies nivolumab [3, 4] and pembrolizumab [5, 6] and anti–PD-L1 antibody atezolizumab [7] and durvalumab [8, 9], were approved for treatment of non–small cell lung carcinoma (NSCLC) by the United States Food and Drug Administration (FDA). Nivolumab [10] and atezolizumab [11] were approved in 2015 and 2016, respectively, as second-line therapies for patients with advanced NSCLC that progressed after or during platinum-based chemotherapy. Pembrolizumab was approved in 2015 as a second-line therapy for patients with advanced NSCLC with PD-L1 expression of ≥1% [12]. In 2016, pembrolizumab was approved as a first-line therapy for NSCLC with PD-L1 expression of ≥50% in tumor tissues and for advanced NSCLC which has PD-L1 expression of ≥1% and has disease progression on or after platinum-containing chemotherapy [12]. More recently, pembrolizumab in combination with pemetrexed and carboplatin was approved by the FDA as first-line therapy for NSCLC [13], while durvalumab was approved for treatment of patients with unresectable stage III NSCLC whose cancer have not progressed following treatment with chemotherapy and radiation [8, 9].

Clinical trials have revealed that using anti-PD immunotherapy for patients with advanced NSCLC led to improved clinical outcomes, including improved survival rates, prolonged duration of response, and reduced treatment-related adverse effects [14]. However, although anti–PD-1 and anti–PD-L1 therapies have shown unprecedented durable responses in some NSCLC...
patients, emerging data from clinical trials with anti-PD therapy also revealed that only about 15–25% of NSCLC patients responded to immune checkpoint blockade [3–5, 7], and most had primary resistance. Thus, predictive biomarkers need to be identified for patient stratification in order to maximize the therapeutic benefit of immune checkpoint blockade therapy; furthermore, approaches to overcome resistance to this anticancer immunotherapy are highly desirable in order to broaden the patient populations who can benefit from this therapy. This review discusses recent progress in translational and clinical investigation of immune checkpoint blockade therapy for lung cancer and factors associated with the treatment responses. We first review the currently available immune checkpoint blockade therapies for treatment of non-small cell lung cancer (NSCLC), and then discuss biomarkers associated with the treatment responses, and analyze possible mechanisms underlying resistance and strategies to overcome resistance.

Clinical responses to immune checkpoint inhibitors in NSCLC

Since 2015, four PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, atezolizumab and durvalumab) have been approved by the FDA as second-line therapy and/or first-line therapy for NSCLC. In addition, anti-PD-L1 antibody avelumab [15] is being evaluated extensively in clinical trials for treatment of NSCLC.

Nivolumab is a human antibody (IgG4) specific for human PD-1. It binds PD-1 with high affinity and prevents interaction of PD-1 with its ligands PD-L1 or PD-L2, thereby enhancing tumor antigen-specific T cell proliferation [16]. The human IgG4 immunoglobulin subtype interacts poorly with Fc receptors (FcγRII and FcγRIII) and complement [17], and thus causing minimal antibody-dependent cell-mediated cytotoxicity and/or complement-induced cytotoxicity to the T cells to be activated. In phase 1 and 2 trials, nivolumab showed durable antitumor activity and a cumulative response rate of about 18% in all NSCLC subtypes [18–20]. In two phase 3 studies comparing the efficacies of nivolumab versus docetaxel in advanced squamous (CheckMate 017) [4] and nonsquamous (CheckMate 057) [3] NSCLC that were resistant to platinum-based therapy, nivolumab was found to be significantly better than docetaxel in response rate, overall survival, and progression-free survival, regardless of intratumoral PD-L1 expression levels. The overall response rate was 19–20% in the nivolumab treated group versus 9–12% in docetaxel treated group (Table 1). Based on those results, nivolumab was approved by the FDA in 2015 as a second-line monotherapy for advanced squamous cell and non-squamous cell NSCLC.

Pembrolizumab (KEYTRUDA) is a humanized IgG4 monoclonal antibody specific for human PD-1. In a randomized phase 2 and 3 trial (KEYNOTE-010) with 1034 NSCLC patients who were previously treated with chemotherapy and were PD-L1–positive in tumor cells based on immunohistochemical analysis (≥1%) [21] (Table 1), patients were randomly assigned to three arms: pembrolizumab at 2 mg/kg, pembrolizumab at 10 mg/kg, and docetaxel at 75 mg/m². The results showed that, among patients with at least 50% of tumor cells expressing PD-L1, overall survival (OS) and progression-free survival (PFS) were significantly longer in the group treated with pembrolizumab at 2 mg/kg than the group treated with docetaxel (median OS was 14.9 months vs 8.2 months, respectively; median PFS 5.0 months vs 4.1 months, respectively) and with pembrolizumab at 10 mg/kg than with docetaxel (median OS was 17.3 months vs 8.2 months, respectively; median PFS 5.2 months vs 4.1 months, respectively) [21]. In another phase 3 trial (KEYNOTE-024) with 305 advanced NSCLC patients who were not previously treated and had no sensitizing mutation for target therapies in their tumors but had at least 50% PD-L1+ tumor cells, patients were randomly assigned to the treatment with either pembrolizumab (200 mg every 3 weeks) or platinum-based chemotherapy [22]. The results revealed that both PFS and estimated OS at 6 months were significantly improved in pembrolizumab treated group than in the chemotherapy group. The response rate was about 45% in the pembrolizumab group vs approximately 28% in the chemotherapy group. Those results led to pembrolizumab’s approval as second-line therapy for metastatic NSCLC with PD-L1 expression of ≥1% and first-line therapy for NSCLC with expression of PD-L1 of ≥50%.

Atezolizumab is an anti-PD-L1 antibody that previously approved by the FDA for the treatment of urothelial carcinoma that progresses after platinum-based chemotherapy. Atezolizumab was recently approved as a second-line therapy for patients with metastatic NSCLC based on two international trials (OAK and POPLAR, Table 1) with a total of 1137 NSCLC patients, which demonstrated consistent results in efficacy and safety atezolizumab in treatment of NSCLC [7, 23]. In comparison with docetaxel, treatment with atezolizumab led to a 2.9–4.2 month improvement in OS in these two trials. The median OS was about 13 months in the atezolizumab treated group compared with about 9.6 months in the docetaxel treated group [7, 23]. The improvement in OS was associated with increased expression of PD-L1 in tumor cells and increased tumor-infiltrating immune cells [23].

Durvalumab is a PD-L1 specific human IgG1 monoclonal antibody [24] that contains three point mutations in the constant domain for minimized binding to complement and Fc receptors [25]. Durvalumab was recently approved for treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy [26]. In a phase III trial (PACIFIC) of 709
stage III NSCLC patients who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy, durvalumab was found to have significantly better PFS, response rate, median time to death or distant metastasis, and OS when compared with placebo [8, 9], which led to FDA’s approval of durvalumab for treatment of unresectable stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy.
and radiation therapy. The PFS and OS benefits with durvalumab were observed irrespective of PD-L1 expression before chemoradiotherapy based the stratification of PD-L1 ≥ 25% or < 25%. In another trial (ATLANTIC) with 444 NSCLC patients enrolled in three cohorts, it was found that the proportion of patients with EGFR+/ALK− NSCLC achieving a response was higher than that with EGFR+/ALK+ NSCLC, nevertheless durvalumab activity was observed in patients with EGFR+ NSCLC whose tumor has ≥25% PD-L1 expression [27].

**Predictive biomarkers associated with response to ICI**

Multiple biomarkers have emerged as being associated with treatment responses to immune checkpoint blockade therapies, including tumor mutational load [28, 29], DNA mismatch repair deficiency [30, 31], composition of gut microbiome [32, 33], intensity of CD8+ cell infiltration [34] and intratumoral PD-L1 expression [35].

The presence of tumor-specific antigens and the interaction of immune cells with tumor antigens are the two basic principles of cancer immunology. Tumor antigens can derive from mutant proteins, overexpressed or dysregulated embryonic proteins, and oncogenic viral proteins. Increased nonsynonymous mutation burden in tumor tissues was expected to increase neoantigens in tumor, leading to stronger immune response against cancer cells. Indeed, clinical trials in lung cancer and melanoma have shown that high tumor mutation burden (TMB) was significantly associated with better objective response, durable clinical benefit, and prolonged progression-free survival for patients treated with ICI [28, 29]. Analysis on data of ICI therapy available in literature for 27 cancer types revealed a significant correlation between the TMB and the objective response rate of anti-PD-1/PD-L1 therapies [36]. In a randomized phase III trial with stage IV or recurrent NSCLC, nivolumab as first-line therapy was found not superior to chemotherapy in PFS or response rate in patients whose tumor had PD-L1 expression of ≥5%. However, nivolumab was found to have higher response rate and longer PFS than chemotherapy among patients with high TMB [37]. Nevertheless, in another phase III trial with stage IV or recurrent NSCLC that was not previously treated with chemotherapy, no significant difference in PFS was found between nivolumab monotherapy and chemotherapy in patients with high TMB [38]. However, TMB was found to be strongly associated with efficacy of ICI combination therapy and was independent of PD-L1 expression [38, 39]. High TMB predicted better objective response, durable benefit and longer PFS in patients treated with nivolumab plus ipilimumab when compared with chemotherapy, of regardless PD-L1 expression. In patients with a low TMB, however, nivolumab plus ipilimumab didn’t provide a benefit over chemotherapy, suggesting that ICI combination therapy alone is insufficient to overcome the resistance caused by low immunogenicity in tumors.

Lung cancer is known to have high TMB when compared with other cancers [40], presumably because lung is directly exposed to mutagens present in tobacco smoke. The average mutation frequency in lung cancer is more than 10-fold higher in smokers than in never-smokers [41]. In fact, molecular smoking signature is significantly associated with improved PFS in patients treated with pembrolizumab, although self-reported smoking history did not significantly associate with benefit of pembrolizumab treatment [28]. In addition to direct exposure to mutagens, driver mutations in genes involved in DNA replication and repair pathways drastically impact on the scale of mutation load [42]. For example, cancers with loss-of-function mutations in genes required for DNA mismatch repair, such as MLH1, MSH2, MSH6, and PMS2, are known to have increased microsatellite instability and to have 100- to 600-fold increases in gene mutation rates [43, 44]. Most solid tumors contain, on average, 60 to 140 nonsynonymous mutations in their genome [40, 45], whereas cancers with mismatch repair deficiency contain, on average, 1400 to 1600 nonsynonymous mutations [31]. Tumors with DNA mismatch repair deficiencies showed greater densities of CD8+ tumor-infiltrating lymphocytes (TILs) and higher PD-L1 expression, and improved response rates and higher survival rates were achieved when patients with these tumors were treated with immune checkpoint inhibitors [30, 31]. DNA mismatch repair deficiency and/or microsatellite instability are detected in about 10% to 15% of colorectal, ovarian, gastric, and endometrial cancers [46–48]. Nevertheless, DNA mismatch repair deficiency or microsatellite instability is detected in less than 1% of NSCLC [49, 50].

High neoantigen burden in tumors are expected to trigger an anticancer immune response, recruiting immune cells to cancer sites and leading to increased levels of TILs, especially effector CD8+ T cells, and immune regulatory cells, such as helper T cells, Tregs, dendritic cells, and macrophages at the cancer site. Activation of T lymphocytes by tumor antigen ultimately leads to production and secretion of IFNγ, a cytokine that stimulates TIL proliferation and differentiation, thereby enhancing TILs effector functions. Paradoxically, IFNγ also trigger TIL apoptosis by inducing PDL1 expression in the tumor microenvironment [51–53], which causes to a negative-feedback that eventually inhibits antitumor immunity.

PD-L1 is not expressed in most normal tissues. However, its expression can be induced by some cancer drivers [54, 55] or by IFNγ [56, 57]. IFNγ-induced PD-L1 expression has a unique histopathological pattern, which is usually focal rather than diffuse and is expressed in cells
adjacent to TILs, as observed in most human cancers [51, 58, 59]. Therefore, both increased TIL levels and increased expression of PD-L1 in the tumor tissues can serve as surrogate biomarkers of immunogenicity of cancer cells and interactions between cancer cells and immune cells or of the presence of adaptive immune resistance [58, 60, 61]. It has been proposed that, based on the presence or absence of PD-L1 expression and TILs, the tumor microenvironment can be classified into four groups [62, 63]: 1) TIL and PD-L1 double-positive, suggesting the presence of adaptive immune resistance; tumor will likely benefit from PD-L1/PD-1 blockade therapy; 2) TIL and PD-L1 double-negative, indicating immune ignorance or lack of detectable immune reaction; tumor will likely not to benefit from ICI therapy; 3) TIL-negative but PD-L1-positive; indicating that PD-L1 expression in cancers is independent of IFNγ but is intrinsic through oncogenic signaling; tumor may not respond to immune checkpoint inhibitors; and 4) TIL-positive but PD-L1-negative, indicating that other immune-suppressive mechanisms may mediate immune tolerance; targeting alternative immune suppressive pathways will be required to restore anticaner immunity. This classification of the tumor microenvironment provides some insight to the discordant results observed in clinics and suggests that PD-L1 expression alone may not completely predict the response to immune checkpoint blockade therapy. Higher levels of PD-L1 expression in tumor tissues were found to have significantly better response rates and better survival in some ICI clinical trials, such as KEYNOTE-001 [5], CheckMate 057 [3], and POPLAR [23]. However, expression of PD-L1 was neither prognostic nor predictive of clinical benefit in CheckMate 017 [4]. In addition, intratumoral heterogeneity of neoantigens [64], different methods (distinct immunohistochemistry antibody clones, staining methods, and scoring systems), and different cutoff values in clinical evaluation of PD-L1 may have also led to discordant results [65].

Lymphocytes reactive to neoantigens

Evidence has shown that intensive lymphocytes infiltrations in tumor stroma and/or intraepithelial tumor nest are associated with better prognosis in lung cancer [66–69]. For example, a study with more than 1500 cases of resectable NSCLC patients has showed that about 10% of NSCLC patients had intense lymphocytic infiltration in their tumors and this subset of patients had improved overall survival than the patients with nonintense tumor lymphocyte infiltration [68]. In particular, high density of CD8+ and/or CD4+ T cells in tumor stroma were independent favorable prognostic factors for NSCLC [66, 67, 69]. More recently, it has been shown that a subset of memory T cells, designated as tissue resident memory T cells (TRM), resident in tissues and do not recirculate via bloodstream. The majority of these TRM cells express CD69 and CD103. Higher density of TRM cells in tumors was recently reported to be predictive of a better survival outcome in lung cancer [70–72]. CD8+CD103+ TIL freshly isolated from NSCLC specimens often express both PD-1 and TIM-3. This TIL subset is found to have increased activation-induced cell death and is capable of mediating specific cytolytic activity against autologous tumor cells when PD-1/PD-L1 interaction was blocked [70, 71].

Evidence has shown that naïve T cells are more effective than memory T cells and that central memory T cells (TCM) are more effective than effector memory T cells (TEM) in adoptive cellular therapy for cancers [73–75]. Analysis on a subpopulation of TILs in melanoma showed that tumor-reactive CD8+ T cells were largely derived from CD8+PD-1+ T cells, even though the level of PD-1 expression on CD8+ tumor-specific TILs decreased during culture with IL-2 [76, 77]. PD-1 overexpression is frequently detected in CD8+ T cells freshly isolated from melanoma, followed by TIM-3, 4-1BB, and LAG-3 [77]. Moreover substantial coexpression of these four receptors was detected on a subset of CD8+ TILs. Expression of TIM-3, LAG-3, and 4-1BB was almost exclusively present on PD-1+ cells. Up-regulation of multiple inhibitory receptors in CD8+ cells was observed in chronic antigen stimulation, including chronic infection, and is known to be associated with T-cell exhaustion [78, 79]. Interestingly, CD8+PD-1+ cells isolated from the peripheral blood of melanoma patients are also neoantigen-reactive [80]. Tumor antigen (including mutated neoantigens, cancer germline antigens, and viral antigens)-specific T cells can be obtained from both tumor tissues and autologous peripheral blood from CD8+PD-1- cell populations (at frequencies of about 0.4–0.002% in blood) [80–82]. The tumor antigen-specific CD4+ or CD8+ TILs targeting mutant ERBB2/2IP and KRAS have been shown to have high anticancer activity in patients [83, 84]. Of interest, the tumor-antigen specificities and TCR repertoires of the CD8+PD-1- cells from peripheral blood and tumor tissues are similar [80], suggesting that the circulating CD8+PD-1- T cells might be a novel noninvasive approach of adoptive cell therapy with neoantigen-reactive lymphocytes, or serve as a surrogate biomarker for adaptive immune resistance.

Resistence to immune checkpoint inhibitors

The mechanisms of resistance to immune checkpoint blockade therapy are not yet well characterized but likely involve multiple factors. A recent study showed that abnormal gut microbiome composition due to the use of antibiotics before immune therapy inhibited the clinical benefit of immune checkpoint blockade therapy in cancer patients [33]. Several oncogenes and tumor suppressor
genes have been reported to affect efficacy of ICI therapy [85–87]. Also, the presence of parallel immune inhibitory pathways and the loss of antigen presentation in cancer cells can be a common mechanism of resistance.

Activating mutations in the EGFR gene are found in approximately 10–17% of lung adenocarcinoma in Caucasians and in approximately 30–65% of lung adenocarcinoma patients in Asia [88]. Clinical trials with nivolumab [3], pembrolizumab [21], atezolizumab [7], and durvalumab [8] showed no significant survival benefit in EGFR-mutant patients treated with these ICIs. A meta-analysis on data from randomized trials of ICIs in NSCLC also found that no significant improvement in OS in the EGFR mutant subgroup treated with ICIs, although prolonged OS was observed in whole study populations and in the EGFR wild-type subgroup when compared with patients treated with docetaxel [86]. It is not clear whether the EGFR-mutant cancers have lower TMB than EGFR-wild-type tumors. Intriguingly, treatment with ICIs was found to result in accelerated tumor growth and clinical deterioration in a subset of patients when compared with pretherapy. Genomic alterations in the MDM2/MDM4 and EGFR genes were found to be correlated with this “hyperprogressor” phenotype [87]. Genomic alterations in the STK11 gene are another factor reported to cause ICI resistance in NSCLC [85]. In lung adenocarcinoma patients with KRAS mutations, co-mutations in STK11 were associated with inferior clinical outcome following PD-1 blockade therapy. STK11 mutations are significantly enriched among tumors with intermediate/high TMB and negative PD-L1 expression. Moreover, knockout of Stk11 resulted in resistance to PD-1 blockade therapy in a Kras-mutant syngeneic mouse model [85], demonstrating STK11 mutations are a causal factor of resistance to ICIs.

Presence of parallel immune inhibitory pathways has been extensively investigated as the causal factors in ICI resistance. For example, indoleamine-2,3-dioxygenase (IDO), a metabolic enzyme that catalyzes the rate-limiting step of tryptophan degradation, has been reported to play a critical role in immunotherapy targeting CTLA-4 [89]. Induced by inflammatory signals such as prostaglandins, IFNγ, and tumor necrosis factor alpha (TNF-α) [90], IDO functions as a key mediator in activating and maintaining the immune suppressive function of Treg cells [91]. Coexpression of multiple T-cell inhibitory receptors (TCIRs), including PD-1, CTLA4, TIM3, and LAG3, in activated and/or exhausted T cells, suggested that parallel inhibitory pathways may mediate resistance to ICI therapy targeting a single TCIR and that simultaneous inhibition of multiple TCIRs may be required to improve therapeutic efficacy. Upregulation of TIM3 was found in PD-1 antibody bound T cells in both murine models of lung adenocarcinoma and in lung cancer patients with adaptive resistance to anti-PD-1 therapy [92]. Sequential PD-1 and TIM3 blockade prolonged survival in a mouse tumor model, indicating potential benefit of anti-PD-1 and anti-TIM3 combination therapy. Prolonged interferon signaling was reported to augment expression of interferon-stimulated genes, including multiple TCIRs and their ligands, leading to resistance to the ICI [93]. Impaired human leukocyte antigen (HLA) class I antigen processing and presentation due to homologous loss or down-regulation of B2M has also been found as a mechanism of acquired resistance to ICIs in lung cancer patients [94, 95]. CRISPR-mediated knock-out of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo [94], demonstrating the causal relationship between loss of B2m and resistance to ICIs.

Because ICIs primarily target the immunosuppressive signals at cancer sites by locoregional blockade of negative feedbacks induced by inhibitory receptors [59], the absence of CTLs at tumor tissues, as observed in most cancer patients [58, 63], could be a major barriers for ICI therapy [35, 59]. In contrast, inflammatory signals are known to strongly augment activated T-cell homing to region of infection [96, 97]. It has been reported that presence of local infection and/or expression of foreign genes, T cell activations were induced by even very weak interactions between T-cell receptors and their ligands, resulting in rapid proliferation and amplification of immune effector and memory cells [98]. Thus, we hypothesized that resistance to ICI therapy caused by low immunogenicity of cancer cells or lack of immune cell infiltration at cancer sites might be overcome by inducing lymphocyte infiltration at cancer sites through installment of locoregional inflammatory signals.

To test this hypothesis, we investigated the effects of anti-PD therapy in combination with locoregional adenovirotherapy in the syngeneic lung cancer model M109. We found that the M109 tumor does not express PD-L1, does not have CD8+ or CD4+ lymphocyte infiltration in cancer tissues, and is resistant to both anti-PD-1 and anti–PD-L1 treatments. Intratumoral administration of an oncolytic adenovirus led to dramatic intratumoral infiltration of both CD4+ and CD8+ lymphocytes and sensitized the M109 tumor to the treatment of anti–PD-L1 or anti–PD-1 antibodies [99]. This result provided a proof-of-concept evidence that resistance ICIs in lung cancer can be overcome by locoregional virotherapies. A similar result was observed in a clinical trial of combination therapy of pembrolizumab with talimogene laherparepvec, a modified herpes simplex virus type 1 that selectively replicates in tumors and expresses granulocyte-macrophage colony-stimulating factor (GM-CSF), in patients with advanced melanoma [100]. IFNγ gene expression in tumor cells after talimogene laherparepvec treatment, increased CD8+ T cells and elevated PD-L1 protein expression were
detected in cancers of the patients who responded to the combination therapy. In addition, baseline CD8+ T-cell infiltration or baseline IFNγ signature were not associated with the response to the combination therapy, suggesting that locoregional virotherapy may overcome primary resistance to ICI therapy by modulating the tumor immune microenvironment.

Promoting lymphocyte infiltration in tumors by other approaches, such as by targeted delivery of LIGHT (TNFSF14) gene to the tumor [101] or by targeted type I IFN activation through peritumoral injections of immunostimulatory RNA (poly:IC) [102], has also been shown to overcome resistance to anti–PD-1 and/or anti–PD-L1 therapies, demonstrating that the presence of lymphocytes at cancer sites is the basis for effective immunotherapy with ICIs.

**Future prospects**

Currently, the testing of PD-L1 expression in the tumor microenvironment [5] and testing for the presence of mismatched repair deficiency in tumor cells [103], which correlates with microsatellite instability and tumor mutational burden, have been approved by the FDA for guidance of ICI therapy in clinics. However, PD-L1 expression is often highly heterogeneous within a tumor and often in disagreement between the primary tumor and the metastatic lesions [104–106], which poses a challenge in using the information obtained from analysis of single small biopsy samples in clinical practice. Knowledge gained from adoptive cell therapy might provide some new ideas in searching for novel predictive biomarkers. For example, it might be interesting to determine whether levels or dynamic changes of CD8+PD-1+ T cells in peripheral blood [80, 107] are associated with treatment responses to ICIs.

Identification of new therapeutic targets and/or development of new therapeutic agents that modulate immune responses will broaden the applications of immunotherapy for cancers. Similarly, strategies that enhance immunogenicity of tumor cells or attract immune cells to cancer sites are expected to be effective approaches to overcoming primary resistance. Indeed, locoregional oncolytic virotherapy has been shown to sensitize tumors resistant to anti–PD-1 or anti–PD-L1 therapy preclinically and clinically [99, 100], presumably because locoregional inflammatory signals promote lymphocyte infiltration at cancer sites. Therapeutic approaches that induce immunogenicity of cancer cells, such as inducing immunogenic cell death [108] by radiotherapy [109, 110], chemotherapy [111], or chemoradiotherapy [112], are also expected to attract lymphocytes to cancer sites, thereby sensitizing tumors to ICI therapy. Therefore, combining ICIs with therapies that promote immunogenicity in tumors or attract lymphocytes to cancer sites will likely be further pursued both preclinically and clinically. A recent phase III trial in patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations showed that standard chemotherapy plus pembrolizumab resulted in significantly longer OS and PFS than chemotherapy alone [113]. The benefit of adding pembrolizumab was observed in all subgroups, including those with PD-L1 expression of < 1%, demonstrating feasibility of enhancing immunogenicity in tumors via chemotherapy. On the other hand, loss of antigen presentation caused by genetic alterations in genes involved antigen presentations, such as B2M [94] and HLA [84], has been reported in acquired resistance to antineoplastic immune therapy. Overcoming the resistance caused by a loss of antigen presentation may require strategies that eliminate cancers independent of HLA, such as adoptive cell therapy with NK cells or chimeric antigen receptor T cells. Progress has also been made in the field of adoptive cellular therapy [114]. The knowledge gained from both ICIs and adoptive cell therapy is expected to have a tremendous impact on the clinical practice of immunotherapy for lung cancer.

**Abbreviations**

FDA: The United States Food and Drug Administration; GM-CSF: Granulocyte-macrophage colony-stimulating factor; HLA: Human leukocyte antigen; HR: Hazard ratio; ICI: Immune checkpoint inhibitor; IDO: Indoleamine-2,3-dioxygenase; IFN: Interferon; ITT: Intent to treat; NK: Natural killer; NSCLC: Non-small cell lung cancer; ORR: Objective response rate; OS: Overall survival; PD-1: Programmed death 1; PD-L1: Programmed death ligand 1; PFS: Progression-free survival; PS: Proportion score; Sq: Squamous; TOR: T-cell inhibitory receptor; TIL: Tumor-infiltrating lymphocyte; TIM3: T-cell immunoglobulin mucin-3; TMB: Tumor mutation burden; TNF: Tumor necrosis factor alpha; Treg: T regulatory cell

**Acknowledgments**

We thank Tamara K. Locke and the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for editorial review of the manuscript. This work was supported by National Institutes of Health/National Cancer Institute grantR01CA190628 and by endowed funds to the University of Texas MD Anderson Cancer Center, including the Sister Institution Network Fund.

**Availability of data and materials**

The data cited in this manuscript can be found in the cited articles.

**Authors’ contributions**

XP and BF conceived the project. XP, LW, DS, WM, and BF collected references and wrote the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details
1Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 2Department of Thoracic Medical Oncology, Hunan Cancer Hospital/the affiliated Cancer Hospital of Xiangya school of Medicine, Central South University, 283 Tongzipo Road, Yuelu District, Changsha 410013, Hunan, China. 3Department of Pathology, Zhejiang Cancer Hospital, 38 Guanji Road, Banshan Bridge, Hangzhou 310022, Zhejiang, China. 4Department of Thoracic Surgery, Zhejiang Cancer Hospital, 38 Guanji Road, Banshan Bridge, Hangzhou 310022, Zhejiang, China.

Received: 3 September 2018 Accepted: 24 October 2018

Published online: 08 November 2018

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
3. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.
4. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhard WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
5. Garon EB, Rizvi NA, Hui R, Leighl N, Biesma B, Schiller JS, Ansell SM, Schadendorf D, Altiok T, Vicente D, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.
6. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Cossío T, Poppleton H, Gottfried M, Peled N, Trafierski A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2015;373(19):1823–33.
7. Odunsi K, Gao X, Farhat H, Metzelder J, Chmelik A, Buchli A, Zhang W, Liao Z, Haas W, Blank TL, et al. Pembrolizumab versus docetaxel for patients with previously untreated advanced non-small-cell lung cancer: results from a phase 2 Randomised controlled trial. Lancet. 2017;389(10066):255–65.
8. Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, Corral EE, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2016;375(15):1452–61.
9. Brown JR, Winters DM, Taylor DR, Horn L, Leighl N, Ramalingam SS, Kim JH, Pluzanski A, Vokes EE, Holgado E, et al. Atezolizumab versus chemotherapy for previously untreated, PD-L1-positive, stage IIIb non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10080):966–75.
10. Kazandjian D, Szumian DL, Blumenthal G, Mushi S, He K, Libog M, Keegan P, Pazdur R. FDA approval summary: Nivolumab for the treatment of metastatic non-small-cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–42.
11. Steinbock K, Khozin S, Szumian D, Zhang L, Tang S, Wahby S, Goldberg KB, Kim G, Pazdur R, U.S. Food and Drug Administration approval summary: Atezolizumab for metastatic non-small-cell lung cancer. Clin Cancer Res. 2017;23(16):4334–9.
12. Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small-cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. 2016;21(5):643–50.
13. Pai-Schefl L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyanis PS, He K, Zhao H, Yu J, Paciga M, Goldberg KB, et al. FDA approval summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist. 2017. https://doi.org/10.1634/theoncologist.2017-0078.
14. Ettinger DS, Wood DE, Asner DL, Akerley W, Bauman J, Chiricle LR, D’Amico TA, DeCamps MM, Dilling TJ, Doboecker N, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(4):504–35.
15. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DIL, Leach J, Edenfield WJ, Wang D, Grote HU, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN solid tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):599–610.
16. Brahmer JR, Drake CG, Wollner I, Pownderly JD, Picus J, Sharhman WH, Stankievich E, Pons A, Salay TM, McMillier TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.
17. Davies AM, Rispens T, Ooijevaar-de Heer P, Gould HJ, Jeffers R, Aalberse RC, Sutton B. Structural determinants of unique properties of human IgG4-Fc. Mol Biol. 2014;426(3):630–44.
18. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia S, Rizvi NA, Pownderly JD, Reis RS, Carvalho RD, Jackman DM, et al. Overall survival and long-term safety of Nivolumab (anti-programmed death-1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.
19. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Pownderly JD, Carvalho RD, Rosam JN, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
20. Rizvi NA, Mazieres J, Planach D, Stinchcombe TE, Dy GK, Antonia S, Horn L, Lena H, Menenza E, Mennecler E, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet. 2015;161(3):257–65.
21. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Anido-C, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.
22. Beck M, Rodriguez-Abreu D, Robinson AG, Hu R, Cossío T, Fulop A, Gottfried M, Peled N, Trafierski A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.
microbiome influences efficacy of PD-1-based immunotherapy against epithelial cancer. Science. 2018;359(6371):91-7.

34. Tumeh PC, Hao S, Yearley JH, Shintaku IP, Taylor EA, Robert L, Shintaku IP, Yearley JH, Harview CL, Yearley JH. Genomic features of tumor mutational burden and response to anti-PD-L1 antibody MPDL3280A in patients with advanced non-small-cell lung cancer. Science. 2014;343(6175):1250-1.

35. Hellmann MD, Krepler R, Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415-26.

36. Hellmann MD, Papadopoulos N, Kwiatkowski DJ, Atlafat A, et al. Predictive correlates of response to anti-PD-L1 antibody MPDL3280A in patients with advanced non-small-cell lung cancer. Nat Med. 2014;20(11):1593-1600.

37. Hellmann MD, Papadopoulos N, Kwiatkowski DJ, Atlafat A, et al. Predictive correlates of response to anti-PD-L1 antibody MPDL3280A in patients with advanced non-small-cell lung cancer. Nat Med. 2014;20(11):1593-1600.

38. Hellmann MD, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415-26.

39. Hellmann MD, Papadopoulos N, Kwiatkowski DJ, Atlafat A, et al. Predictive correlates of response to anti-PD-L1 antibody MPDL3280A in patients with advanced non-small-cell lung cancer. Nat Med. 2014;20(11):1593-1600.

40. Hellmann MD, Papadopoulos N, Kwiatkowski DJ, Atlafat A, et al. Predictive correlates of response to anti-PD-L1 antibody MPDL3280A in patients with advanced non-small-cell lung cancer. Nat Med. 2014;20(11):1593-1600.
76. Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010;33(9):956–64.

77. Goso A, Robbins PF, Yao X, Yu YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Fard S, Dudley ME, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–59.

78. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29–37.

79. Baitsch L, Legat A, Barba L, Fuertes Maraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One. 2012;7(2):e30852.

80. Goso A, Parkhurst MR, Tran E, Passotti A, Robbins PF, Ilyas S, Polley TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prognostic importance of human melanoma CD8+ T cells expressing inhibitory receptors. Cancer Res. 2013;73(6):1842–50.

81. Tran E, Turcotte S, Goso A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunity based on mutation-specific CD8+ T cells in patients with epithelial cancer. Science. 2014;344(6184):641–5.

82. Stevanovic S, Passotti A, Helman SR. Landscape of immunogenic tumor antigens in successful immunotherapy of viral-induced epithelial cancer. Nat Immunol. 2016;17:977–88.

83. Tate SE, de Kruif J, Wunderlich JR, Rosenberg SA, Fong Y, Trinchet J-L, Groh EM, et al. T-cell transfer therapy targeting mutant KRAS in adenocarcinoma. Cancer Discov. 2018;8:822–33.

84. Nakamura S, Hayashi K, Imakita Y, Kitamura Y, Akaza Y, Tabata K, Groen R, Tsuchiya T, Yamazaki N, Hayagata Y, et al. Intratumoral heterogeneity of programmed death-1 ligand expression is common in lung cancer. PLoS One. 2017;12(10):e0186192.

85. Pinato DJ, Shiner RJ, White SD, Black JR, Trivedi P, Stebbing J, Sharma R, Mauri FA. Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: implications for immunotherapy. Oncoimmunology. 2016;5(9):e1213934.

86. Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koening L, Patel NT, et al. Proliferation of PD-1+CD8+ T cells in peripheral blood after PD-1 targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114(19):4953–8.

87. Kepp O, Sennovilla L, Vitalé I, Vacchelli E, Agermann S, Agostinis P, Apetch L, Arianda F, Babamra V, Bloy N, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3(9):e955691.

88. Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology. 2013;2(10):e26536.

89. Gallo M, Brossa M, Perona M, Grassi L, Galleazzi V, et al. Profound PD-L1 morphologic expression in colorectal cancer (CheckMate 817): results from a randomized phase III trial of nivolumab versus chemotherapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1554/e1512.

90. Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, Murata T, Torrejon DY, Abril-Rodriguez G, Sandovall S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(8):789–99.

91. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272(5258):60–6.

92. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol. 2012;13(3):209–20.

93. Zeh D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature. 2009;458(7235):211–4.

94. Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz WJ, Zhang X, Wang JF, Gibbons DL, et al. Overcoming resistance to anti-PD-1 immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology. 2018;7(1):e1376156.

95. Ribas A, Dummer R, Puzanov I, VanderWalde RL, Andtbacka RH, Michielin O, Olzanski AJ, Malvehy J, Cebron J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109–1119.e1110.

96. Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Xu YX. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-1 blockade. Cancer Cell. 2016;29(3):285–96.

97. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014;4(6):674–87.

98. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelsson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite-instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–9.

99. Gettinger SN, Chiarion-Sileni V, Kim KB, Lee HW, Ma刺 SM, et al. Tumor-infiltrating CD8+ T cells mediate clinical responses to programmed death-1 blockade in patients with melanoma. Oncotarget. 2016;7(19):25483–93.

100. Ribas A, Dummer R, Puzanov I, VanderWalde RL, Andtbacka RL, Michielin O, Olzanski AJ, Malvehy J, Cebron J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109–1119.e1110.

101. Ribas A, Dummer R, Puzanov I, VanderWalde RL, Andtbacka RL, Michielin O, Olzanski AJ, Malvehy J, Cebron J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109–1119.e1110.

102. Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Xu YX. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-1 blockade. Cancer Cell. 2016;29(3):285–96.

103. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014;4(6):674–87.

104. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelsson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite-instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–9.

105. Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology. 2013;2(10):e26536.

106. Gallo M, Brossa M, Perona M, Grassi L, Galleazzi V, et al. Profound PD-L1 morphologic expression in colorectal cancer (CheckMate 817): results from a randomized phase III trial of nivolumab versus chemotherapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1554/e1512.

107. Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, Murata K, Fuji H, Nakano T, Kono K. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 2012;72(16):3976–97.

108. Gandhi L, Rodriguez-Abruña D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer. N Engl J Med. 2018;378(22):2078–92.

109. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566–81.